Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?
Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that indication. However, the optimal sequencing of ther...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2023-12-01
|
| Series: | Exploration of Targeted Anti-tumor Therapy |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/etat/Article/1002198 |
| _version_ | 1797374120600535040 |
|---|---|
| author | Sabah Alaklabi Arya Mariam Roy Lubna N. Chaudhary Shipra Gandhi |
| author_facet | Sabah Alaklabi Arya Mariam Roy Lubna N. Chaudhary Shipra Gandhi |
| author_sort | Sabah Alaklabi |
| collection | DOAJ |
| description | Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that indication. However, the optimal sequencing of therapy remains an unanswered question for a subset of mTNBC patients who harbor germline breast cancer gene 1/2 (BRCA1/2; gBRCA1/2) mutation. This article aims to offer insights into the optimal therapy sequencing for mTNBC patients with gBRCA1/2 mutations and its impact on clinical decision-making. The perspective offered is based on the best currently available data and propose a practical algorithm to guide the management of this subgroup in the frontline setting. |
| first_indexed | 2024-03-08T19:00:17Z |
| format | Article |
| id | doaj.art-daec0b61338044bbb23da71553b951f5 |
| institution | Directory Open Access Journal |
| issn | 2692-3114 |
| language | English |
| last_indexed | 2024-03-08T19:00:17Z |
| publishDate | 2023-12-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Targeted Anti-tumor Therapy |
| spelling | doaj.art-daec0b61338044bbb23da71553b951f52023-12-28T05:21:22ZengOpen Exploration Publishing Inc.Exploration of Targeted Anti-tumor Therapy2692-31142023-12-01461301130910.37349/etat.2023.00198Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?Sabah Alaklabi0Arya Mariam Roy1https://orcid.org/0000-0003-2509-312XLubna N. Chaudhary2https://orcid.org/0000-0003-0616-6135Shipra Gandhi3https://orcid.org/0000-0003-3506-0284Department of Medical Oncology, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi ArabiaDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USADivision of Hematology/Oncology, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USADepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USAPembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that indication. However, the optimal sequencing of therapy remains an unanswered question for a subset of mTNBC patients who harbor germline breast cancer gene 1/2 (BRCA1/2; gBRCA1/2) mutation. This article aims to offer insights into the optimal therapy sequencing for mTNBC patients with gBRCA1/2 mutations and its impact on clinical decision-making. The perspective offered is based on the best currently available data and propose a practical algorithm to guide the management of this subgroup in the frontline setting.https://www.explorationpub.com/Journals/etat/Article/1002198metastatic triple-negative breast cancerprogrammed cell death ligand-1poly (adp-ribose) polymerase inhibitorsequencing of therapytargeted therapy |
| spellingShingle | Sabah Alaklabi Arya Mariam Roy Lubna N. Chaudhary Shipra Gandhi Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation? Exploration of Targeted Anti-tumor Therapy metastatic triple-negative breast cancer programmed cell death ligand-1 poly (adp-ribose) polymerase inhibitor sequencing of therapy targeted therapy |
| title | Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation? |
| title_full | Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation? |
| title_fullStr | Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation? |
| title_full_unstemmed | Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation? |
| title_short | Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation? |
| title_sort | facing the conundrum which first line therapy should be used for patients with metastatic triple negative breast cancer carrying germline brca mutation |
| topic | metastatic triple-negative breast cancer programmed cell death ligand-1 poly (adp-ribose) polymerase inhibitor sequencing of therapy targeted therapy |
| url | https://www.explorationpub.com/Journals/etat/Article/1002198 |
| work_keys_str_mv | AT sabahalaklabi facingtheconundrumwhichfirstlinetherapyshouldbeusedforpatientswithmetastatictriplenegativebreastcancercarryinggermlinebrcamutation AT aryamariamroy facingtheconundrumwhichfirstlinetherapyshouldbeusedforpatientswithmetastatictriplenegativebreastcancercarryinggermlinebrcamutation AT lubnanchaudhary facingtheconundrumwhichfirstlinetherapyshouldbeusedforpatientswithmetastatictriplenegativebreastcancercarryinggermlinebrcamutation AT shipragandhi facingtheconundrumwhichfirstlinetherapyshouldbeusedforpatientswithmetastatictriplenegativebreastcancercarryinggermlinebrcamutation |